06306393 is referenced by 244 patents and cites 7 patents.

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

Title
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
Application Number
9/307816
Publication Number
6306393 (B1)
Application Date
May 10, 1999
Publication Date
October 23, 2001
Inventor
David M Goldenberg
Mendham
NJ, US
Agent
Foley & Lardner
US
Assignee
Immunomedics
NJ, US
IPC
A61K 39/00
View Original Source